89bio (ETNB) News Today $7.98 -0.01 (-0.13%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period 89bio Announces Pricing of Public OfferingNovember 18 at 2:02 AM | americanbankingnews.comWhat is HC Wainwright's Estimate for 89bio FY2024 Earnings?November 16, 2024 | americanbankingnews.com89bio announces new analyses of data from Phase 2b ENLIVEN trialNovember 15, 2024 | markets.businessinsider.com89bio, Inc. Presents New Data from Phase 2b ENLIVEN Trial of Pegozafermin for Advanced MASH at AASLD 2024November 15, 2024 | quiverquant.com89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024November 15, 2024 | globenewswire.com89bio FY2024 EPS Estimate Decreased by Cantor FitzgeraldNovember 15, 2024 | americanbankingnews.comFY2024 EPS Estimates for 89bio Reduced by Cantor Fitzgerald89bio, Inc. (NASDAQ:ETNB - Free Report) - Analysts at Cantor Fitzgerald dropped their FY2024 earnings estimates for 89bio in a report released on Monday, November 11th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will earn ($2.98) per share for the year, down from their pNovember 14, 2024 | marketbeat.comHC Wainwright Has Pessimistic View of 89bio FY2024 Earnings89bio, Inc. (NASDAQ:ETNB - Free Report) - Stock analysts at HC Wainwright reduced their FY2024 earnings estimates for 89bio in a research report issued on Monday, November 11th. HC Wainwright analyst E. Arce now forecasts that the company will post earnings of ($3.50) per share for the year, downNovember 14, 2024 | marketbeat.com89bio (ETNB) Receives a Hold from OppenheimerNovember 13, 2024 | markets.businessinsider.com89bio announces $100M common stock offeringNovember 13, 2024 | markets.businessinsider.com89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded WarrantsNovember 12, 2024 | globenewswire.com89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded WarrantsNovember 12, 2024 | globenewswire.com89bio, Inc. (NASDAQ:ETNB) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of 89bio, Inc. (NASDAQ:ETNB - Get Free Report) have been given an average recommendation of "Moderate Buy" by the seven analysts that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, four have given aNovember 12, 2024 | marketbeat.com89bio’s Pegozafermin: A Promising Best-in-Class Contender in NASH TreatmentNovember 12, 2024 | markets.businessinsider.comPositive Outlook for 89bio Amid Promising Developments in MASH Clinical ProgramsNovember 12, 2024 | markets.businessinsider.com89bio (NASDAQ:ETNB) Receives Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $29.00 price target on shares of 89bio in a research note on Monday.November 11, 2024 | marketbeat.comFY2028 Earnings Estimate for 89bio Issued By Leerink Partnrs89bio, Inc. (NASDAQ:ETNB - Free Report) - Leerink Partnrs dropped their FY2028 earnings per share (EPS) estimates for shares of 89bio in a note issued to investors on Thursday, November 7th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings per share of $3.99 for thNovember 11, 2024 | marketbeat.com89bio Reports Third Quarter 2024 Financial Results and Corporate UpdatesSAN FRANCISCO, November 7, 2024 (GLOBE NEWSWIRE) - On November 7, 2024, 89bio, Inc. (NASDAQ: ETNB), a clinical-stage biopharmaceutical company focusing on innovative therapies foNovember 11, 2024 | americanbankingnews.com89bio (ETNB) Gets a Hold from RBC CapitalNovember 10, 2024 | markets.businessinsider.comRaymond James Issues Pessimistic Forecast for 89bio (NASDAQ:ETNB) Stock PriceRaymond James dropped their price objective on shares of 89bio from $53.00 to $49.00 and set a "strong-buy" rating for the company in a research note on Friday.November 8, 2024 | marketbeat.com89bio, Inc. (NASDAQ:ETNB) Stock Position Increased by Harbor Capital Advisors Inc.Harbor Capital Advisors Inc. boosted its position in shares of 89bio, Inc. (NASDAQ:ETNB - Free Report) by 165.3% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 227,930 shares of the company's stock after bNovember 6, 2024 | marketbeat.com89bio to Participate in the UBS Global Healthcare ConferenceNovember 5, 2024 | globenewswire.com89bio (NASDAQ:ETNB) Shares Gap Down - Should You Sell?89bio (NASDAQ:ETNB) Shares Gap Down - Here's WhyNovember 4, 2024 | marketbeat.comMadrigal, 89Bio jump after Novo’s semaglutide shows promise in MASHNovember 1, 2024 | markets.businessinsider.com89bio (NASDAQ:ETNB) Trading 7.3% Higher - Time to Buy?89bio (NASDAQ:ETNB) Stock Price Up 7.3% - Time to Buy?November 1, 2024 | marketbeat.com89bio: Surviving A Competitive Space - For NowOctober 29, 2024 | seekingalpha.com89bio, Inc. (NASDAQ:ETNB) Receives Consensus Recommendation of "Moderate Buy" from Analysts89bio, Inc. (NASDAQ:ETNB - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven ratings firms that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and one has assiOctober 18, 2024 | marketbeat.comState Street Corp's Strategic Acquisition in 89bio IncOctober 17, 2024 | finance.yahoo.com89bio, Inc. (NASDAQ:ETNB) Short Interest Down 7.1% in September89bio, Inc. (NASDAQ:ETNB - Get Free Report) was the recipient of a significant decrease in short interest in the month of September. As of September 30th, there was short interest totalling 6,450,000 shares, a decrease of 7.1% from the September 15th total of 6,940,000 shares. Based on an average daily trading volume, of 616,600 shares, the days-to-cover ratio is currently 10.5 days.October 17, 2024 | marketbeat.com89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024October 15, 2024 | globenewswire.com89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 11, 2024 | globenewswire.com89bio, Inc. (NASDAQ:ETNB) Shares Sold by Millennium Management LLCMillennium Management LLC lowered its stake in shares of 89bio, Inc. (NASDAQ:ETNB - Free Report) by 7.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,010,352 shares of the company'sOctober 10, 2024 | marketbeat.com89bio (NASDAQ:ETNB) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comRenaissance Technologies LLC Invests $2.24 Million in 89bio, Inc. (NASDAQ:ETNB)Renaissance Technologies LLC purchased a new position in shares of 89bio, Inc. (NASDAQ:ETNB - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 279,400 shares of the company's stock, valued at approximately $2,23October 3, 2024 | marketbeat.com89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor ConferenceSeptember 30, 2024 | globenewswire.com89bio (NASDAQ:ETNB) Trading Down 2.9%89bio (NASDAQ:ETNB) Stock Price Down 2.9%September 23, 2024 | marketbeat.comIntegral Health Asset Management LLC Buys 150,000 Shares of 89bio, Inc. (NASDAQ:ETNB)Integral Health Asset Management LLC boosted its stake in shares of 89bio, Inc. (NASDAQ:ETNB - Free Report) by 50.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 450,000 shares of the company's sSeptember 23, 2024 | marketbeat.com89bio, Inc. (NASDAQ:ETNB) Receives Average Rating of "Moderate Buy" from AnalystsShares of 89bio, Inc. (NASDAQ:ETNB - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eight analysts that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has givenSeptember 23, 2024 | marketbeat.com89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 19, 2024 | globenewswire.com89bio, Inc.: 89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality OfficerSeptember 17, 2024 | finanznachrichten.de89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality OfficerSeptember 16, 2024 | globenewswire.comCandriam S.C.A. Has $6.79 Million Holdings in 89bio, Inc. (NASDAQ:ETNB)Candriam S.C.A. lifted its position in 89bio, Inc. (NASDAQ:ETNB - Free Report) by 173.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 848,079 shares of the company's stock after purchasing an additSeptember 9, 2024 | marketbeat.comShort Interest in 89bio, Inc. (NASDAQ:ETNB) Rises By 5.2%89bio, Inc. (NASDAQ:ETNB - Get Free Report) saw a large increase in short interest in August. As of August 15th, there was short interest totalling 6,840,000 shares, an increase of 5.2% from the July 31st total of 6,500,000 shares. Based on an average trading volume of 954,000 shares, the days-to-cover ratio is currently 7.2 days.September 3, 2024 | marketbeat.com89bio to Participate in Upcoming Investor ConferencesAugust 30, 2024 | finance.yahoo.com89bio, Inc. (NASDAQ:ETNB) Given Consensus Recommendation of "Moderate Buy" by Analysts89bio, Inc. (NASDAQ:ETNB - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eight analysts that are presently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, five have assigned a buy recommendationAugust 29, 2024 | marketbeat.comShort Interest in 89bio, Inc. (NASDAQ:ETNB) Increases By 5.5%89bio, Inc. (NASDAQ:ETNB - Get Free Report) saw a large growth in short interest during the month of July. As of July 31st, there was short interest totalling 6,500,000 shares, a growth of 5.5% from the July 15th total of 6,160,000 shares. Based on an average trading volume of 985,100 shares, the short-interest ratio is presently 6.6 days.August 18, 2024 | marketbeat.comETNB Sep 2024 12.500 callAugust 18, 2024 | ca.finance.yahoo.comETNB Sep 2024 10.000 callAugust 17, 2024 | ca.finance.yahoo.comETNB Sep 2024 7.500 callAugust 17, 2024 | ca.finance.yahoo.com89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 9, 2024 | globenewswire.com Get 89bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ETNB and its competitors with MarketBeat's FREE daily newsletter. Email Address [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin ETNB Media Mentions By Week ETNB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ETNB News Sentiment▼-0.170.46▲Average Medical News Sentiment ETNB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ETNB Articles This Week▼144▲ETNB Articles Average Week Get 89bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ETNB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MoonLake Immunotherapeutics News Agios Pharmaceuticals News Verona Pharma News PTC Therapeutics News Dyne Therapeutics News Bausch Health Companies News Edgewise Therapeutics News Merus News Xenon Pharmaceuticals News HUTCHMED News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ETNB) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 89bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 89bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ETNB Stock Alerts